These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


165 related items for PubMed ID: 315753

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics.
    Wise R, Andrews JM, Bedford KA.
    Antimicrob Agents Chemother; 1979 Sep; 16(3):341-5. PubMed ID: 507788
    [Abstract] [Full Text] [Related]

  • 3. Antibacterial activity of selected beta-lactam and aminoglycoside antibiotics against cephalothin-resistant Enterobacteriaceae.
    Lewis RP, Meyer RD, Kraus LL.
    Antimicrob Agents Chemother; 1976 May; 9(5):780-6. PubMed ID: 949175
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity and beta-lactamase stability of a new penem, CGP 31608.
    Neu HC, Chin NX, Neu NM.
    Antimicrob Agents Chemother; 1987 Apr; 31(4):558-69. PubMed ID: 3496845
    [Abstract] [Full Text] [Related]

  • 5. Comparative in vitro appraisal of piperacillin, including its activity against Salmonella typhi.
    Robinson RG, Saunders J, Cassel R, Block CS, Koornhof HJ.
    Antimicrob Agents Chemother; 1980 Oct; 18(4):493-501. PubMed ID: 6449903
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'.
    Morinaka A, Tsutsumi Y, Yamada M, Suzuki K, Watanabe T, Abe T, Furuuchi T, Inamura S, Sakamaki Y, Mitsuhashi N, Ida T, Livermore DM.
    J Antimicrob Chemother; 2015 Oct; 70(10):2779-86. PubMed ID: 26089439
    [Abstract] [Full Text] [Related]

  • 8. In-vitro activity of FCE 22101 and synergy studies with other antimicrobial agents.
    Chin NX, Neu HC.
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():95-101. PubMed ID: 2786520
    [Abstract] [Full Text] [Related]

  • 9. In-vitro activity of a new penem FCE 22101.
    Hoban DJ.
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():53-7. PubMed ID: 2786518
    [Abstract] [Full Text] [Related]

  • 10. Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Phillips I, Warren C, Shannon K, King A, Hanslo D.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():23-31. PubMed ID: 19802967
    [Abstract] [Full Text] [Related]

  • 11. Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability.
    Neu HC, Labthavikul P.
    Antimicrob Agents Chemother; 1982 Jan; 21(1):180-7. PubMed ID: 6979306
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antibacterial activity of the cephamycin cefotetan: an in-vitro comparison with other beta-lactam antibiotics.
    Clarke AM, Zemcov SJ.
    J Antimicrob Chemother; 1983 Jan; 11 Suppl():67-72. PubMed ID: 6404881
    [Abstract] [Full Text] [Related]

  • 14. Comparison of in vitro activity of FCE 22101, a new penem, with those of other beta-lactam antibiotics.
    Wise R, Andrews JM, Danks G.
    Antimicrob Agents Chemother; 1983 Dec; 24(6):909-14. PubMed ID: 6607032
    [Abstract] [Full Text] [Related]

  • 15. Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases.
    Livermore DM, Mushtaq S, Warner M, Woodford N.
    J Antimicrob Chemother; 2015 Nov; 70(11):3032-41. PubMed ID: 26311835
    [Abstract] [Full Text] [Related]

  • 16. Inconsistency of synergy between the beta-lactamase inhibitor CP-45,899 and beta-lactam antibiotics against multiply drug-resistant Enterobacteriaceae and pseudomonas species.
    Fass RJ.
    Antimicrob Agents Chemother; 1981 Feb; 19(2):361-3. PubMed ID: 6289732
    [Abstract] [Full Text] [Related]

  • 17. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN, Barry AL, Thornsberry C, Gerlach EH, Fuchs PC, Gavan TL, Sommers HM.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [Abstract] [Full Text] [Related]

  • 18. beta-Lactamase production and susceptibility of US and European anaerobic gram-negative bacilli to beta-lactams and other agents.
    Jacobs MR, Spangler SK, Appelbaum PC.
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1081-93. PubMed ID: 1295763
    [Abstract] [Full Text] [Related]

  • 19. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
    Stratton CW, Weeks LS, Aldridge KE.
    Diagn Microbiol Infect Dis; 1992 Nov; 15(4):321-30. PubMed ID: 1611847
    [Abstract] [Full Text] [Related]

  • 20. The in-vitro activity of a novel penem FCE 22101 compared to other beta-lactam antibiotics.
    Neu HC, Chin NX, Labthavikul P.
    J Antimicrob Chemother; 1985 Sep; 16(3):305-13. PubMed ID: 2997100
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.